论文部分内容阅读
弥漫性血管内凝血是涉及临床多学科的一个重要的病理生理过程,病情重,病死率高。目前,其主要的治疗手段之一仍为肝素抗凝治疗。依据弥漫性血管内凝血(DIC)的病理过程中凝血、纤溶机制的变化,临床上可分为凝亢期、凝溶期和凝衰期。 及时了解患者凝血、纤溶系统的活动情况是临床治疗所必需的,故应动态监测DIC的相关实验室指标。急性DIC时凝血因子消耗性减少,抗凝物质增多,PT延长率达75％,APTT延长率达60％,且两种指标操作简便,成本低,故为国内临床常规采用。DIC患者常接受肝素治疗,而肝素可引起PT、APTT不同程度延长,影响实验室对PT、APTT结果的正确分析和判断。为此,我们就体外不同活性肝素及不同浓度硫酸鱼精蛋白对PT、APTT的影响做了观察。
Diffuse intravascular coagulation is involved in clinical multidisciplinary an important pathophysiological process, severe illness, high mortality. At present, one of the main treatments is still heparin anticoagulant therapy. According to diffuse intravascular coagulation (DIC) in the pathological process of coagulation, fibrinolysis changes in clinical clotting can be divided into coagulation phase, coagulation and coagulation phase. Timely understanding of patients with coagulation, fibrinolytic system activity is necessary for clinical treatment, it should be dynamically monitored DIC related laboratory indicators. Acute DIC coagulation factor depletion, anticoagulant substances increased, PT extended rate of 75%, APTT extension rate of 60%, and the two indicators of easy to operate, low cost, so it is routine clinical use. DIC patients often receive heparin therapy, and heparin can cause PT, APTT extend to varying degrees, affecting the laboratory on the PT, APTT results of the correct analysis and judgments. Therefore, we observed the effects of different active heparin and different concentrations of protamine sulfate on PT and APTT in vitro.